Clinical Trial

Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial studies how well ustekinumab works in preventing acute graft-versus-host disease after unrelated donor hematopoietic cell transplant. Sometimes the transplanted cells from a donor can attack the body's normal tissues (called graft-versus-host disease). Giving ustekinumab after the transplant may help prevent acute graft-versus-host disease by controlling the body's immune response. Funding Source- FDA OOPD.
Protocol Amendment History 27 amendments
This ClinicalTrials.gov record has been amended 27 times since 2020-09-28; most recent amendment 2025-12-30.
Status change: Recruiting → Active, Not Recruiting 2025-05-22
Status change: Suspended → Recruiting 2024-01-31
Status change: Recruiting → Suspended 2023-10-12
Status change: Not Yet Recruiting → Recruiting 2021-04-28
Trial Details
NCT Number NCT04572815
Lead Sponsor Fred Hutchinson Cancer Center
Conditions Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid System Neoplasm
Enrollment 116 participants
Start Date 2021-05-14
Primary Completion 2025-10-27 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-02